HYPERTHERMIA AND CHEMOTHERAPY ON TUMOR AND NORMAL TISSUE

这项研究的总体目标是建立一个最优的 使用热疗和化疗的多模式治疗方案，提供 对临界剂量限制的最大肿瘤消融和最小损害 正常组织。大鼠纤维肉瘤人工转移瘤的疗效观察 将其作为肿瘤模型应用于肺部。然后这些数据将被 与这些正常组织的急性和慢性反应相比 考虑正在测试的特定药物的剂量限制。 确定顺铂、阿霉素和博莱霉素的剂量关系 当与全身热疗同时给予时，肿瘤反应和 为了量化靶区正常组织的急性和迟发性反应 每种药物在与热结合时和单独与热结合时。若要比较 化疗药物在常温下的药代动力学 体温采用连续组织和血清药物分析。要确定 给药时延长热药间隔时间的效果 加热前后对肿瘤反应和靶区正常的影响 组织反应。为了确定生物反应修饰物是否， 维诺鲁通，一种生物类氧自由基清除剂， 受热、用药后优先保留靶区正常组织 治疗。 除了提供对药物的药代动力学的洞察外，当 与热结合，并了解了结合的影响 对正常组织的治疗；从这些研究中获得的数据 联合用药对患者管理的潜在重要性 局部或全身体温过高。

The general objective of this study is to establish an optimum multimodality treatment regimen using heat and chemotherapy that provides both maximum tumor ablation and minimal damage to critical dose limiting normal tissues. The response of a rat fibrosarcoma artificially metastatic to the lung will be used as a tumor model. These data will then be compared to the acute and chronic respones of those normal tissues considered dose limiting for the particular drug being tested. To determine the dose relationships of cisplatin, adriamycin, and bleomycin when given simultaneously with systemic hyperthermia on tumor response and to quantify the acute and late responses of the target normal tissues for each drug when combined with heat and with heat alone. To compare the pharmacokinetics of the chemotherapy agents at normal hyperthermic temperatures using serial tissue and serum drug analysis. To determine the effect of increasing the time interval between heat and drugs when given before and after heating on both the tumor response and the target normal tissue response. To determine if a biological response modifier, venoruton, a bioflavenoid oxyden free radical scavenging agent, preferentially spares the target normal tissue after heat and drug treatment. In addition to providing insight into the pharmacokinetics of drugs when combined with heat, and a knowledge of the effects of the combined therapies on normal tissues; the data obtained from these studies have potential importance to the management of patients using drugs combined with either local-regional or systemic hyperthermia.